Braidwell »

Akero Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Akero Therapeutics (AKRO) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Akero Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Akero Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Akero Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2024-06-30 $25M 1.1M 23.46

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Nuvasive Note 0.375% 3/1 (Principal)
Neurocrine Biosciences (NBIX)
Cg Oncology (CGON)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Neogenomics Note 0.250% 1/1 (Principal)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)
Legend Biotech Corp Sponsored Ads (LEGN)
Dexcom Note 0.250%11/1 (Principal)

View all positions for Braidwell

Top funds holding Akero Therapeutics

Henderson Group
BlackRock
T. Rowe Price Associates
Vanguard Group
State Street Corporation
Alliancebernstein
T. Rowe Price Investment Management
Boxer Capital
Geode Capital Management
Redmile Group
Perceptive Advisors
Yiheng Capital
Baker Bros. Advisors
Braidwell
Rock Springs Capital Management

View all funds holding Akero Therapeutics